Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications

Drug Metabolism and Disposition

Volumn 36, Issue 7, 2008, Pages 1332-1340

  Henshall, Jamie ^a   Galetin, Aleksandra ^a   Harrison, Anthony ^b   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA NAPHTHOFLAVONE; ANDROSTENEDIONE; CARBAMAZEPINE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLAVONE; FLAVONOID; HYDROCORTISONE; PRASTERONE; PRASTERONE SULFATE; PROGESTERONE; QUINIDINE; STEROID HORMONE; TESTOSTERONE;

ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EPOXIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

CARBAMAZEPINE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; ENZYME ACTIVATION; FLAVONOIDS; HEPATOCYTES; HORMONES; HUMANS; KINETICS; MICROSOMES, LIVER; PROTEIN BINDING; RECOMBINANT PROTEINS; STEROIDS; TANDEM MASS SPECTROMETRY;

EID: 46449133208     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.021279     Document Type: Article

References (39)

1. Alworth WL, Dang CC, Ching LM, and Viswanathan T (1980) Stimulation of mammalian epoxide hydrase activity by flavones. Xenobiotica 10:395-400.
2. Austin RP, Barton P, Mohmed S, and Riley RJ (2005) The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab Dispos 33:419-425.
3. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45.
4. Davydov DR, Baas BJ, Sligar SG, and Halpert JR (2007) Allosteric mechanisms in cytochrome P450 3A4 studied by high-pressure spectroscopy: pivotal role of substrate-induced changes in the accessibility and degree of hydration of the heme pocket. Biochemistry 46:7852-7864.
5. Di Renzo GC, Rosati A, Mattei A, Gojnic M, and Gerli S (2005) The changing role of progesterone in preterm labour. BJOG 112 Suppl 1:57-60.
6. Egnell AC, Eriksson C, Albertson N, Houston B, and Boyer S (2003a) Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther 307:878-887.
7. Egnell AC, Houston B, and Boyer S (2003b) In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305:1251-1262.
8. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, and Rane A (1975) Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol 8:337-341.
9. Eichelbaum M, Tomson T, Tybring G, and Bertilsson L (1985) Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet 10:80-90.
10. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, Crane M, Kanik KS, and Chrousos GP (2001) IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 86:4933-4938.
11. Galetin A, Clarke SE, and Houston JB (2002) Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
12. Galetin A, Clarke SE, and Houston JB (2003) Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108-1116.
13. Galetin A and Houston JB (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318: 1220-1229.
14. Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
15. Hallifax D and Houston JB (2006) Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-726.
16. Hansch C, Leo A, and Hoekman D (1995) Exploring QSAR, vol xix, 348 pp and vol xvii, 557 pp. American Chemical Society, Washington, DC.
17. Hollman PC and Katan MB (1997) Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 51:305-310.
18. Houston JB and Galetin A (2005) Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 433:351-360.
19. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
20. Huang W, Lin YS, McConn DJ, Calamia JC, Totah RA, Isoherranen N, Glodowski M, and Thummel KE (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 32:1434-1445.
21. Hummel MA, Locuson CW, Gannett PM, Rock DA, Mosher CM, Rettie AE, and Tracy TS (2005) CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Mol Pharmacol 68:644-651.
22. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmacol Res 22:103-112.
23. Jushchyshyn MI, Hutzler JM, Schrag ML, and Wienkers LC (2005) Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity. Arch Biochem Biophys 438:21-28.
24. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzales FJ, and Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
25. Lander CM and Eadie MJ (1991) Plasma antiepileptic drug concentrations during pregnancy. Epilepsia 32:257-266.
26. Lasker JM, Huang MT, and Conney AH (1984) In vitro and in vivo activation of oxidative drug metabolism by flavonoids. J Pharmacol Exp Ther 229:162-170.
27. McConn DJ, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
28. Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, and Kitada M (2002) Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos 30:534-540.
29. Nakamura H, Torimoto N, Ishii I, Ariyoshi N, Nakasa H, Ohmori S, and Kitada M (2003) CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos 31:432-438.
30. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
31. Pelkonen O, Myllynen P, Taavitsainen P, Boobis AR, Watts P, Lake BG, Price RJ, Renwick AB, Gomez-Lechon MJ, Castell JV, et al. (2001) Carbamazepine: a "blind" assessment of CVP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 31:321-343.
32. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV, and Korzekwa KR (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
33. Sumi M, Watari N, Umezawa O, and Kaneniwa N (1987) Pharmacokinetic study of carbamazepine and its epoxide metabolite in humans. J Pharmacobiodyn 10:652-661.
34. Svinarov DA and Pippenger CE (1996) Relationships between carbamazepinediol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: the influence of age, sex, and comedication. Ther Drug Monit 18:660-665.
35. Tang W and Stearns RA (2001) Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2:185-198.
36. Tang W, Stearns RA, Kwei GY, Iliff SA, Miller RR, Egan MA, Yu NX, Dean DC, Kumar S, Shou M, et al. (1999) Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism. J Pharmacol Exp Ther 291:1068-1074.
37. Torimoto N, Ishii I, Hata M, Nakamura H, Imada H, Ariyoshi N, Ohmori S, Igarashi T, and Kitada M (2003) Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 42:15068-15077.
38. Venkatakrishnan K, Von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
39. Xie HG, Wood AJ, Kim RB, Stein CM, and Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.